STAMFORD, Conn., Dec 03, 2003 -- Novogen Limited (Nasdaq: NVGN) has been granted the U.S. patent covering health supplements based on the use of soy isoflavones in tablet or capsule form.
This patent has been licensed worldwide, with the exception of Australia and New Zealand, to Solae LLC of St Louis, Mo. Solae is a joint venture of the DuPont Company and Bunge.
The issuance of the patent is a valuable addition to the patent portfolio of Novogen in the area of isoflavones and health supplements as well as an important licensing milestone between the Company and Solae.
Based upon this newly issued patent, Solae has initiated a new patent infringement suit in the U.S. against both Archer Daniels Midland Company and Amerfit Inc.
Novogen is also listed in Australia (ASX: NRT). The company manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).